Estimating prevalence from dried blood spots without using biological cut-offs: application of a novel approach to hepatitis C virus in drug users in France (ANRS-Coquelicot survey).
Adult
Bayes Theorem
Cross-Sectional Studies
Dried Blood Spot Testing
/ methods
Drug Users
/ statistics & numerical data
Enzyme-Linked Immunosorbent Assay
/ methods
Female
France
/ epidemiology
Hepacivirus
/ isolation & purification
Hepatitis C
/ diagnosis
Hepatitis C Antibodies
/ blood
Humans
Male
Middle Aged
Predictive Value of Tests
Prevalence
RNA, Viral
/ blood
Reproducibility of Results
Risk Assessment
Specimen Handling
Cut-off
drug users
hepatitis C virus
mixture model
prevalence
Journal
Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
entrez:
1
8
2019
pubmed:
1
8
2019
medline:
3
4
2020
Statut:
ppublish
Résumé
Seroprevalence estimation using cross-sectional serosurveys can be challenging due to inadequate or unknown biological cut-off limits of detection. In recent years, diagnostic assay cut-offs, fixed assay cut-offs and more flexible approaches as mixture modelling have been proposed to classify biological quantitative measurements into a positive or negative status. Our objective was to estimate the prevalence of anti-HCV antibodies among drug users (DU) in France in 2011 using a biological test performed on dried blood spots (DBS) collected during a cross-sectional serosurvey. However, in 2011, we did not have a cut-off value for DBS. We could not use the values for serum or plasma, knowing that the DBS value was not necessarily the same. Accordingly, we used a method which consisted of applying a two-component mixture model with age-dependent mixing proportions using penalised splines. The component densities were assumed to be log-normally distributed and were estimated in a Bayesian framework. Anti-HCV prevalence among DU was estimated at 43.3% in France and increased with age. Our method allowed us to provide estimates of age-dependent prevalence using DBS without having a specified biological cut-off value.
Identifiants
pubmed: 31364569
pii: S0950268819001043
doi: 10.1017/S0950268819001043
pmc: PMC6625185
doi:
Substances chimiques
Hepatitis C Antibodies
0
RNA, Viral
0
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e220Références
Epidemiol Infect. 2003 Apr;130(2):285-91
pubmed: 12729197
Epidemiol Infect. 2006 Dec;134(6):1303-12
pubmed: 16650326
Sex Transm Dis. 2006 Sep;33(9):545-50
pubmed: 16735957
Public Health Rep. 2006 Nov-Dec;121(6):710-9
pubmed: 17278406
Vaccine. 2008 Aug 12;26(34):4403-9
pubmed: 18585420
Drug Alcohol Rev. 2008 Nov;27(6):666-70
pubmed: 19378449
Hepatology. 2010 Mar;51(3):752-8
pubmed: 20043287
Antiviral Res. 2012 Mar;93(3):309-21
pubmed: 22244848
J Clin Virol. 2014 Apr;59(4):223-7
pubmed: 24529844
Epidemiology. 2015 Jan;26(1):8-16
pubmed: 25380503
Biostatistics. 2015 Jul;16(3):565-79
pubmed: 25597489
Epidemiol Infect. 2016 Mar;144(4):887-95
pubmed: 26311119
J Infect Dis. 2016 Apr 1;213(7):1087-95
pubmed: 26333945
Epidemiol Infect. 2015 Nov;143(15):3292-9
pubmed: 26418350
Br J Dermatol. 2016 Jan;174(1):104-12
pubmed: 26473766
Rev Epidemiol Sante Publique. 2016 Sep;64(4):301-12
pubmed: 26904917
BMC Infect Dis. 2016 Aug 02;16:364
pubmed: 27484304
PLoS One. 2016 Sep 30;11(9):e0163636
pubmed: 27689800
Epidemiol Infect. 2017 Apr;145(5):895-907
pubmed: 28004616
Am J Epidemiol. 2017 Jan 15;185(2):124-134
pubmed: 28062393
PLoS One. 2017 Oct 20;12(10):e0186722
pubmed: 29053737